ABP 168
Alternative Names: ABP-168Latest Information Update: 28 Jun 2023
At a glance
- Originator Atom Bioscience
- Class Antigouts
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gout
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Gout in China
- 30 May 2019 Atom Bioscience has patent protection for xanthine oxidase inhibitor compounds in China, Japan, Europe, USA and World before May 2019 (Atom Bioscience website, May 2019)
- 01 May 2019 Early research in Gout in China before May 2019 (Atom Bioscience website, May 2019)